Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998785 | 0.79 | NFE2L2 (0.39) | NFE2L2HTT | |
| SCHEMBL2998788 | 0.79 | NFE2L2 (0.39) | NFE2L2HTT | |
| SCHEMBL13625315 | 0.78 | NOS2 (0.33) | — | |
| SCHEMBL21615529 | 0.78 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL12775976 | 0.77 | NFE2L2 (0.35) | NFE2L2HTT | |
| SCHEMBL9942225 | 0.75 | HTT (0.34) | NFE2L2HTT | |
| SCHEMBL678617 | 0.75 | EGFR (0.36) | NFE2L2HTT | |
| SCHEMBL14414777 | 0.75 | HTT (0.34) | NFE2L2HTT | |
| SCHEMBL29253838 | 0.74 | L3MBTL1 (0.38) | NFE2L2 | |
| SCHEMBL19373816 | 0.73 | EGFR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
| US-9290506-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150218174-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2015-08-06 | — | — | US | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993582-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8883806-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
| US-20150218174-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | NFE2L2 2937/4885HTT 4421/4885GALR3 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.